Spots Global Cancer Trial Database for Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

Official Title:

Study ID: NCT02749526

Conditions

Esophageal

Interventions

"Endostar"

Liposo

cisplatin

Gimeracil and Oteracil Potassium （Tegafur）

Study Description

Brief Summary: Endostar ® (recombinant human endostatin) continuous intravenous infusion combined with mPFC neoadjuvant treatment of esophageal cancer arm, Ⅱ single-center clinical trial.

Detailed Description: 1. Research purpose: Endostar (recombinant human endostatin) continuous intravenous infusion combined with chemotherapy for stage Ⅲ resectable or potentially resectable esophageal cancer efficacy and safety and to maintain the efficacy and safety. 2. The main objectives: R0 resection rate Secondary objectives: 1. pCR rate 2. 3-year disease-free survival 3. Security and complications 4. DFS, OS 5. Quality of Life 3.The number of research centers and research time: This study intends to preside and implemented by the Jiangsu Provincial People's Hospital, Professor Gu Yanhong. The trial is scheduled to start in September 2015, planned to stop in June 2016 into the group, one patient surgery follow-up to the last end, get the primary endpoint and safety, surgical complications secondary endpoint. This study will continue to follow-up the patient DFS, OS and other secondary end points.